Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like SAR444656 and amlitelimab in development.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes ...

Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden ...

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD ... for competition in AD treatment and may introduce a novel therapeutic ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...

Effective management of atopic dermatitis (AD) has been one of the ... paving the way for significant improvements in diagnostics, drug discovery, and personalised medicine. The application ...